drugset / Trial / NCT07640789

A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)

NCT07640789

RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib in patients with unresectable EGFR-mutated Stage III non-small cell lung cancer who have not progressed following platinum-based chemoradiotherapy.

Timeline

Start
2026-06
Primary completion
2030-12
Completion
2030-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Izalontamab Brengitecan Unknown Intravenous
Subject Osimertinib Small molecule Oral